Aqneursa
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- L-acetylleucine
- Made by
- Intrabio Ireland Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Aqneursa is indicated for the treatment of neurological manifestations of Niemann-Pick type C (NPC) disease, in combination with miglustat, or as a monotherapy in patients where miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
NetherlandsNo exact match for this strength and form
Details
| Made by | Intrabio Ireland Limited |
|---|---|
| Active substance | L-acetylleucine |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N07XX27 · Pain, sleep, mood, epilepsy and the brain |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-01-19 |
| Last updated by the regulator | 2026-03-03 |
| EMA product number | EMEA/H/C/006327 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).